Public disclosures

RCKT insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
Shah Gaurav

CEO · ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 1051358 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

2026-11-182026-11-20

≈ $4,826.45

2,216 shares/units

SEC 4Follow
Wilson Martin

General Counsel · ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 540336 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

2026-11-182026-11-20

≈ $1,474.51

677 shares/units

SEC 4Follow
Shah Gaurav

CEO · ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 1053574 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

2026-11-132026-11-17

≈ $6,795.00

3,020 shares/units

SEC 4Follow
Wilson Martin

General Counsel · ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 541013 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

2026-11-132026-11-17

≈ $9,195.75

4,087 shares/units

SEC 4Follow
Chaudhuri Sarbani

See Remarks · ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 257937 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. · Chief Commercial & Medical Affairs Officer

2026-11-092026-11-12

≈ $11,337.14

4,872 shares/units

SEC 4Follow
Wilson Martin

General Counsel · ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 545100 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

2026-11-052026-11-09

≈ $127,813.27

53,389 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement